<DOC>
	<DOC>NCT01023282</DOC>
	<brief_summary>The study will evaluate the safety and tolerability of ACR325 in Parkinson disease patients and evaluate the effect on levodopa induced dyskinesias.</brief_summary>
	<brief_title>Safety and Tolerability Study Evaluating ACR325 in Parkinson's Disease Patients</brief_title>
	<detailed_description />
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Levodopa</mesh_term>
	<criteria>Diagnosis of idiopathic Parkinsonâ€Ÿs disease according to the United Kingdom Parkinson's Disease Society brain bank diagnostic criteria Levodopa induced dyskinesia Previous surgery for Parkinson's disease Any current or history of heart condition or increased proarrhythmic risk Severe or ongoing unstable medical condition</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>June 2011</verification_date>
	<keyword>Parkinson's disease</keyword>
	<keyword>Levodopa</keyword>
	<keyword>Dyskinesia</keyword>
	<keyword>ACR325</keyword>
</DOC>